CN Patent

CN121868226A — Glp-1组合物及其用途

Assigned to Novo Nordisk AS · Expires 2026-04-17 · 0y expired

What this patent protects

本发明涉及包含不超过0.1%（w/w）的苯酚和高于6.4 mg/ml的氯化钠的GLP‑1肽司美格鲁肽的药物组合物、其制备、包含这类组合物的试剂盒及其用途。

USPTO Abstract

本发明涉及包含不超过0.1%（w/w）的苯酚和高于6.4 mg/ml的氯化钠的GLP‑1肽司美格鲁肽的药物组合物、其制备、包含这类组合物的试剂盒及其用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN121868226A
Jurisdiction
CN
Classification
—
Expires
2026-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.